Cargando…

Effect of Rivastigmine on Behavioral and Psychiatric Symptoms of Parkinson’s Disease Dementia

OBJECTIVE: A recent study showed that rivastigmine and memantin improved behavioral and psychiatric symptoms of dementia (BPSD) in Alzheimer’s dementia. Furthermore, according to recent guidelines presented by the Movement Disorder Society, rivastigmine is efficacious for the treatment of dementia i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oh, Yoon-Sang, Kim, Joong-Seok, Lee, Phil Hyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Movement Disorders Society 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4460546/ https://www.ncbi.nlm.nih.gov/pubmed/26090082 http://dx.doi.org/10.14802/jmd.15041

Ejemplares similares

Neuropsychiatric Symptoms in Parkinson’s Disease Dementia Are Associated with Increased Caregiver Burden
por: Oh, Yoon-Sang, et al.
Publicado: (2015)

Rivastigmine for the treatment of dementia associated with Parkinson’s disease
por: Reingold, Jennifer L, et al.
Publicado: (2007)

The Effects of Rivastigmine on Neuropsychiatric Symptoms in the Early Stages of Parkinson's Disease: A Systematic Review
por: Reilly, Siobhan, et al.
Publicado: (2023)

Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson’s disease dementia
por: Kandiah, Nagaendran, et al.
Publicado: (2017)

Two cases of Alzheimer’s disease showing deterioration of behavioral and psychological symptoms of dementia induced by switching from rivastigmine to donepezil
por: Kimura, Takemi, et al.
Publicado: (2013)

Rivastigmine as a Symptomatic Treatment for Apathy in Parkinson's Dementia Complex: New Aspects for This Riddle
por: Moretti, Rita, et al.
Publicado: (2017)

Rivastigmine in Chinese patients with subcortical vascular dementia
por: Mok, Vincent, et al.
Publicado: (2007)

Analysis of the Substantia Innominata Volume in Patients with Parkinson’s Disease with Dementia, Dementia with Lewy Bodies, and Alzheimer’s Disease
por: Kim, Hee Jin, et al.
Publicado: (2011)

Transient receptor potential V1 modulates neuroinflammation in Parkinson’s disease dementia: Molecular implications for electroacupuncture and rivastigmine
por: Tsai, Sheng-Ta, et al.
Publicado: (2021)

An interpretable multiparametric radiomics model of basal ganglia to predict dementia conversion in Parkinson’s disease
por: Park, Chae Jung, et al.
Publicado: (2023)

Validation of the Korean-Version of the Nonmotor Symptoms Scale for Parkinson's Disease
por: Koh, Seong-Beom, et al.
Publicado: (2012)

Behavioral and Psychiatric Symptoms of Dementia and Rate of Decline in Alzheimer’s Disease
por: Gottesman, Reena T., et al.
Publicado: (2019)

Esophagectasis Related to Rivastigmine
por: Sasaki, Osamu, et al.
Publicado: (2019)

Rivastigmine in the treatment of Alzheimer’s disease: an update
por: Onor, Maria Luisa, et al.
Publicado: (2007)

Rivastigmine in the treatment of patients with Alzheimer’s disease
por: Müller, Thomas
Publicado: (2007)

Emerging Concepts of Motor Reserve in Parkinson’s Disease
por: Chung, Seok Jong, et al.
Publicado: (2020)

Potential Link Between Cognition and Motor Reserve in Patients With Parkinson’s Disease
por: Chung, Seok Jong, et al.
Publicado: (2022)

The diagnostic potential of multimodal neuroimaging measures in Parkinson's disease and atypical parkinsonism
por: Park, Chang‐hyun, et al.
Publicado: (2020)

The ReSPonD trial - rivastigmine to stabilise gait in Parkinson’s disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson’s disease who have fallen
por: Henderson, Emily J, et al.
Publicado: (2013)

Patients and Their Caregivers’ Burdens for Parkinson’s Disease in Korea
por: Baik, Jong Sam, et al.
Publicado: (2017)

Orthostatic and Supine Blood Pressures Are Associated with White Matter Hyperintensities in Parkinson Disease
por: Oh, Yoon-Sang, et al.
Publicado: (2013)

Premorbid cancer and motor reserve in patients with Parkinson’s disease
por: Oh, Yoon-Sang, et al.
Publicado: (2022)

Effects of a Rivastigmine Patch on Self-Care Activities in Patients with Alzheimer's Disease plus Cerebrovascular Disease
por: Kim, Yong Kyun, et al.
Publicado: (2014)

EXACT: rivastigmine improves the high prevalence of attention deficits and mood and behaviour symptoms in Alzheimer's disease*
por: Gauthier, S, et al.
Publicado: (2007)

Psychiatric Symptoms in Patients and Caregivers with Parkinson’s Disease
por: Saadat, Payam, et al.
Publicado: (2020)

Improper Application of a Rivastigmine Patch to the Back of the Neck Induced Toxic Symptoms
por: Matsuzono, Kosuke, et al.
Publicado: (2023)

Rivastigmine in Alzheimer’s disease: Cognitive function and quality of life
por: Annicchiarico, Roberta, et al.
Publicado: (2007)

Once-daily transdermal rivastigmine in the treatment of Alzheimer’s disease
por: Wentrup, Andreas, et al.
Publicado: (2009)

Author Correction: Premorbid cancer and motor reserve in patients with Parkinson’s disease
por: Oh, Yoon‑Sang, et al.
Publicado: (2022)

Subjective Cognitive Complaints in Cognitively Normal Patients With Parkinson’s Disease: A Systematic Review
por: Hong, Jin Yong, et al.
Publicado: (2023)

Effects of rivastigmin tartarat in the therapy of patients with schizophrenia
por: Djordjevic, Snezana, et al.
Publicado: (2010)

Acquired Localized Hypertrichosis Induced by Rivastigmine
por: Imbernón-Moya, Adrian, et al.
Publicado: (2016)

Rivastigmine for minor visual hallucinations in Parkinson's disease: A randomized controlled trial with 24 months follow‐up
por: van Mierlo, Tom J. M., et al.
Publicado: (2021)

Efficacy and Safety of Switching from Oral Cholinesterase Inhibitors to the Rivastigmine Transdermal Patch in Patients with Probable Alzheimer's Disease
por: Han, Hyun Jeong, et al.
Publicado: (2011)

The Impact of Impulsivity on Quality of Life in Early Drug-Naïve Parkinson’s Disease Patients
por: Ryu, Dong-Woo, et al.
Publicado: (2019)

The Impact of Impulsivity on Quality of Life in Early Drug-Naïve Parkinson’s Disease Patients
por: Ryu, Dong-Woo, et al.
Publicado: (2021)

Association between Olfactory Deficit and Motor and Cognitive Function in Parkinson’s Disease
por: Yoo, Han Soo, et al.
Publicado: (2020)

The presence of depression in de novo Parkinson’s disease reflects poor motor compensation
por: Lee, Yoonju, et al.
Publicado: (2018)

The Effect of Rivastigmine Transdermal Patch on Sleep Apnea in Patients with Probable Alzheimer's Disease
por: Kim, Hyeyun, et al.
Publicado: (2016)

Translation and Validation of the Korean Version of the 39-Item Parkinson's Disease Questionnaire
por: Kwon, Do-Young, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_co0cfiasvbv6ess8uuh0at1u67